Literature DB >> 33177202

TRAF6 and TAK1 Contribute to SAMHD1-Mediated Negative Regulation of NF-κB Signaling.

Constanza E Espada1, Corine St Gelais2, Serena Bonifati2, Victoria V Maksimova2, Michael P Cahill1, Sun Hee Kim2, Li Wu3.   

Abstract

Sterile alpha motif and HD domain-containing protein 1 (SAMHD1) restricts HIV-1 replication by limiting the intracellular deoxynucleoside triphosphate (dNTP) pool. SAMHD1 also suppresses the activation of NF-κB in response to viral infections and inflammatory stimuli. However, the mechanisms by which SAMHD1 negatively regulates this pathway remain unclear. Here, we show that SAMHD1-mediated suppression of NF-κB activation is modulated by two key mediators of NF-κB signaling, tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) and transforming growth factor β-activated kinase 1 (TAK1). We compared NF-κB activation stimulated by interleukin (IL)-1β in monocytic THP-1 control and SAMHD1 knockout (KO) cells with and without partial TRAF6 knockdown (KD), or in cells treated with TAK1 inhibitors. Relative to control cells, IL-1β-treated SAMHD1 KO cells showed increased phosphorylation of the inhibitor of NF-κB (IκBα), an indication of pathway activation, and elevated levels of TNF-α mRNA. Moreover, SAMHD1 KO combined with TRAF6 KD or pharmacological TAK1 inhibition reduced IκBα phosphorylation and TNF-α mRNA to the level of control cells. SAMHD1 KO cells infected with single-cycle HIV-1 showed elevated infection and TNF-α mRNA levels compared to control cells, and the effects were significantly reduced by TRAF6 KD or TAK1 inhibition. We further demonstrated that overexpressed SAMHD1 inhibited TRAF6-stimulated NF-κB reporter activity in HEK293T cells in a dose-dependent manner. SAMHD1 contains a nuclear localization signal (NLS), but an NLS-defective SAMHD1 exhibited a suppressive effect similar to the wild-type protein. Our data suggest that the TRAF6-TAK1 axis contributes to SAMHD1-mediated suppression of NF-κB activation and HIV-1 infection.IMPORTANCE Cells respond to pathogen infection by activating a complex innate immune signaling pathway, which culminates in the activation of transcription factors and secretion of a family of functionally and genetically related cytokines. However, excessive immune activation may cause tissue damage and detrimental effects on the host. Therefore, in order to maintain host homeostasis, the innate immune response is tightly regulated during viral infection. We have reported SAMHD1 as a novel negative regulator of the innate immune response. Here, we provide new insights into SAMHD1-mediated negative regulation of the NF-κB pathway at the TRAF6-TAK1 checkpoint. We show that SAMHD1 inhibits TAK1 activation and TRAF6 signaling in response to proinflammatory stimuli. Interestingly, TRAF6 knockdown in SAMHD1-deficient cells significantly inhibited HIV-1 infection and activation of NF-κB induced by virus infection. Our research reveals a new negative regulatory mechanism by which SAMHD1 participates in the maintenance of cellular homeostasis during HIV-1 infection and inflammation.
Copyright © 2021 Espada et al.

Entities:  

Keywords:  HIV-1; NF-κB activation; SAMHD1; TAK1; TRAF6; inflammation; regulation

Mesh:

Substances:

Year:  2021        PMID: 33177202      PMCID: PMC7925110          DOI: 10.1128/JVI.01970-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease.

Authors:  Juliane Totzke; Deepak Gurbani; Rene Raphemot; Philip F Hughes; Khaldon Bodoor; David A Carlson; David R Loiselle; Asim K Bera; Liesl S Eibschutz; Marisha M Perkins; Amber L Eubanks; Phillip L Campbell; David A Fox; Kenneth D Westover; Timothy A J Haystead; Emily R Derbyshire
Journal:  Cell Chem Biol       Date:  2017-08-17       Impact factor: 8.116

2.  Naf1 Regulates HIV-1 Latency by Suppressing Viral Promoter-Driven Gene Expression in Primary CD4+ T Cells.

Authors:  Chuan Li; Hai-Bo Wang; Wen-Dong Kuang; Xiao-Xin Ren; Shu-Ting Song; Huan-Zhang Zhu; Qiang Li; Li-Ran Xu; Hui-Jun Guo; Li Wu; Jian-Hua Wang
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

3.  TAK1 Lys-158 but not Lys-209 is required for IL-1β-induced Lys63-linked TAK1 polyubiquitination and IKK/NF-κB activation.

Authors:  Yihui Fan; Yang Yu; Renfang Mao; Hong Zhang; Jianhua Yang
Journal:  Cell Signal       Date:  2010-12-03       Impact factor: 4.315

4.  Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutières syndrome.

Authors:  Georgia Ramantani; Jürgen Kohlhase; Christoph Hertzberg; A Micheil Innes; Kerstin Engel; Susan Hunger; Wiktor Borozdin; Jean K Mah; Kristina Ungerath; Hartmut Walkenhorst; Hans-Helmut Richardt; Johannes Buckard; Andrea Bevot; Corinna Siegel; Celina von Stülpnagel; Chrysanthy Ikonomidou; Kara Thomas; Virginia Proud; Frank Niemann; Dagmar Wieczorek; Martin Häusler; Pascal Niggemann; Volkan Baltaci; Karsten Conrad; Pierre Lebon; Min Ae Lee-Kirsch
Journal:  Arthritis Rheum       Date:  2010-05

Review 5.  The role of ubiquitin in NF-kappaB regulatory pathways.

Authors:  Brian Skaug; Xiaomo Jiang; Zhijian J Chen
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

Review 6.  LPS/TLR4 signal transduction pathway.

Authors:  Yong-Chen Lu; Wen-Chen Yeh; Pamela S Ohashi
Journal:  Cytokine       Date:  2008-03-04       Impact factor: 3.861

Review 7.  Cell type-specific function of TAK1 in innate immune signaling.

Authors:  Adebusola A Ajibade; Helen Y Wang; Rong-Fu Wang
Journal:  Trends Immunol       Date:  2013-05-07       Impact factor: 16.687

8.  Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response.

Authors:  Gillian I Rice; Jacquelyn Bond; Aruna Asipu; Rebecca L Brunette; Iain W Manfield; Ian M Carr; Jonathan C Fuller; Richard M Jackson; Teresa Lamb; Tracy A Briggs; Manir Ali; Hannah Gornall; Lydia R Couthard; Alec Aeby; Simon P Attard-Montalto; Enrico Bertini; Christine Bodemer; Knut Brockmann; Louise A Brueton; Peter C Corry; Isabelle Desguerre; Elisa Fazzi; Angels Garcia Cazorla; Blanca Gener; Ben C J Hamel; Arvid Heiberg; Matthew Hunter; Marjo S van der Knaap; Ram Kumar; Lieven Lagae; Pierre G Landrieu; Charles M Lourenco; Daphna Marom; Michael F McDermott; William van der Merwe; Simona Orcesi; Julie S Prendiville; Magnhild Rasmussen; Stavit A Shalev; Doriette M Soler; Marwan Shinawi; Ronen Spiegel; Tiong Y Tan; Adeline Vanderver; Emma L Wakeling; Evangeline Wassmer; Elizabeth Whittaker; Pierre Lebon; Daniel B Stetson; David T Bonthron; Yanick J Crow
Journal:  Nat Genet       Date:  2009-06-14       Impact factor: 38.330

9.  SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells.

Authors:  Benjamin Descours; Alexandra Cribier; Christine Chable-Bessia; Diana Ayinde; Gillian Rice; Yanick Crow; Ahmad Yatim; Olivier Schwartz; Nadine Laguette; Monsef Benkirane
Journal:  Retrovirology       Date:  2012-10-23       Impact factor: 4.602

Review 10.  SAMHD1 Functions and Human Diseases.

Authors:  Si'Ana A Coggins; Bijan Mahboubi; Raymond F Schinazi; Baek Kim
Journal:  Viruses       Date:  2020-03-31       Impact factor: 5.048

View more
  3 in total

1.  SAMHD1 Promotes the Antiretroviral Adaptive Immune Response in Mice Exposed to Lipopolysaccharide.

Authors:  BradleyS Barrett; David H Nguyen; Joella Xu; Kejun Guo; Shravida Shetty; Sean T Jones; Kaylee L Mickens; Caitlin Shepard; Axel Roers; Rayk Behrendt; Li Wu; Baek Kim; Mario L Santiago
Journal:  J Immunol       Date:  2021-12-10       Impact factor: 5.426

Review 2.  Mechanistic Interplay between HIV-1 Reverse Transcriptase Enzyme Kinetics and Host SAMHD1 Protein: Viral Myeloid-Cell Tropism and Genomic Mutagenesis.

Authors:  Nicole E Bowen; Adrian Oo; Baek Kim
Journal:  Viruses       Date:  2022-07-26       Impact factor: 5.818

Review 3.  SAMHD1 … and Viral Ways around It.

Authors:  Janina Deutschmann; Thomas Gramberg
Journal:  Viruses       Date:  2021-03-02       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.